The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Non Alcoholic Fatty Liver Disease Treatment-Global Market Insights and Sales Trends 2024
Synopsis
Fatty liver disease refers to the accumulation of fat (triglycerides,) in the liver. The liver cell contains fats, but the accumulation of excess fat can be a cause of concern and can lead to liver inflammation known as steatohepatitis. The fatty liver can be caused by alcohol as well as can be non-alcohol. Steatohepatitis can cause liver cirrhosis (fibrosis, scarring, and hardening of the liver). The cause of non-alcoholic fatty liver disease (NAFLD) is unknown. The nonalcoholic fatty liver disease (NAFLD) is one of the most common diseases in the United States. The prevalence of nonalcoholic fatty liver disease (NAFLD) is rising due to rise in prevalence of diabetes and obesity. According to National Health and Nutrition Examination survey, about 20-30% of the general population in the western world suffer from nonalcoholic fatty liver disease (NAFLD). The common symptoms include fatigue, weakness, weight loss and others. The diagnosis of NAFLD requires the combination of different tests such as blood test, ultrasound, CT scan, MRI scan, and liver biopsy. The two types of Nonalcoholic fatty liver disease (NAFLD) includes simple fatty liver and Nonalcoholic Steatohepatitis (NASH). The simple fatty liver is a type of nonalcoholic fatty liver (NAFL), in which fat is deposited, but no inflammation or liver damage is observed. NASH is the inflammation of the liver due to excess fat deposit and can lead to liver damage and disease.
The global Non Alcoholic Fatty Liver Disease Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Non Alcoholic Fatty Liver Disease Treatment in various end use industries. The expanding demands from the Hospital Pharmacy, Retail Pharmacy, Drug Stores and Online Pharmacy, are propelling Non Alcoholic Fatty Liver Disease Treatment market. Antioxidants, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Thiazolidinedione segment is estimated at % CAGR for the next seven-year period.
North America is estimated to lead the global nonalcoholic fatty liver disease treatment market due to increase in prevalence of diabetes and cardiovascular diseases in United States. Large number of manufacturers exist in the market, with large number of customer base. Asia Pacific market is also projected to experience high growth in the near future owing to factors such as, increase in healthcare expenditure, rising standard of living, lifestyle changes- attributed to better healthcare and awareness of the cost-effective treatment process with government grants and funding for acceleration in research and development activities.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Non Alcoholic Fatty Liver Disease Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Non Alcoholic Fatty Liver Disease Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Non Alcoholic Fatty Liver Disease Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Non Alcoholic Fatty Liver Disease Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Non Alcoholic Fatty Liver Disease Treatment covered in this report include Pfizer, Roche, Daewoong, Cardax, Merck, Novartis, Gilead Sciences, AstraZeneca and Limerick BioPharma, etc.
The global Non Alcoholic Fatty Liver Disease Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Roche
Daewoong
Cardax
Merck
Novartis
Gilead Sciences
AstraZeneca
Limerick BioPharma
GW Pharmaceuticals
Allergan
Takeda Pharmaceutical
Global Non Alcoholic Fatty Liver Disease Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Non Alcoholic Fatty Liver Disease Treatment market, Segment by Type:
Antioxidants
Thiazolidinedione
Biguanides
Lipid lowering Agents
FXR Receptor Agonist
Others
Global Non Alcoholic Fatty Liver Disease Treatment market, by Application
Hospital Pharmacy
Retail Pharmacy
Drug Stores
Online Pharmacy
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Non Alcoholic Fatty Liver Disease Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Fatty liver disease refers to the accumulation of fat (triglycerides,) in the liver. The liver cell contains fats, but the accumulation of excess fat can be a cause of concern and can lead to liver inflammation known as steatohepatitis. The fatty liver can be caused by alcohol as well as can be non-alcohol. Steatohepatitis can cause liver cirrhosis (fibrosis, scarring, and hardening of the liver). The cause of non-alcoholic fatty liver disease (NAFLD) is unknown. The nonalcoholic fatty liver disease (NAFLD) is one of the most common diseases in the United States. The prevalence of nonalcoholic fatty liver disease (NAFLD) is rising due to rise in prevalence of diabetes and obesity. According to National Health and Nutrition Examination survey, about 20-30% of the general population in the western world suffer from nonalcoholic fatty liver disease (NAFLD). The common symptoms include fatigue, weakness, weight loss and others. The diagnosis of NAFLD requires the combination of different tests such as blood test, ultrasound, CT scan, MRI scan, and liver biopsy. The two types of Nonalcoholic fatty liver disease (NAFLD) includes simple fatty liver and Nonalcoholic Steatohepatitis (NASH). The simple fatty liver is a type of nonalcoholic fatty liver (NAFL), in which fat is deposited, but no inflammation or liver damage is observed. NASH is the inflammation of the liver due to excess fat deposit and can lead to liver damage and disease.
The global Non Alcoholic Fatty Liver Disease Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Non Alcoholic Fatty Liver Disease Treatment in various end use industries. The expanding demands from the Hospital Pharmacy, Retail Pharmacy, Drug Stores and Online Pharmacy, are propelling Non Alcoholic Fatty Liver Disease Treatment market. Antioxidants, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Thiazolidinedione segment is estimated at % CAGR for the next seven-year period.
North America is estimated to lead the global nonalcoholic fatty liver disease treatment market due to increase in prevalence of diabetes and cardiovascular diseases in United States. Large number of manufacturers exist in the market, with large number of customer base. Asia Pacific market is also projected to experience high growth in the near future owing to factors such as, increase in healthcare expenditure, rising standard of living, lifestyle changes- attributed to better healthcare and awareness of the cost-effective treatment process with government grants and funding for acceleration in research and development activities.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Non Alcoholic Fatty Liver Disease Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Non Alcoholic Fatty Liver Disease Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Non Alcoholic Fatty Liver Disease Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Non Alcoholic Fatty Liver Disease Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Non Alcoholic Fatty Liver Disease Treatment covered in this report include Pfizer, Roche, Daewoong, Cardax, Merck, Novartis, Gilead Sciences, AstraZeneca and Limerick BioPharma, etc.
The global Non Alcoholic Fatty Liver Disease Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Roche
Daewoong
Cardax
Merck
Novartis
Gilead Sciences
AstraZeneca
Limerick BioPharma
GW Pharmaceuticals
Allergan
Takeda Pharmaceutical
Global Non Alcoholic Fatty Liver Disease Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Non Alcoholic Fatty Liver Disease Treatment market, Segment by Type:
Antioxidants
Thiazolidinedione
Biguanides
Lipid lowering Agents
FXR Receptor Agonist
Others
Global Non Alcoholic Fatty Liver Disease Treatment market, by Application
Hospital Pharmacy
Retail Pharmacy
Drug Stores
Online Pharmacy
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Non Alcoholic Fatty Liver Disease Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Non Alcoholic Fatty Liver Disease Treatment
1.1 Non Alcoholic Fatty Liver Disease Treatment Market Overview
1.1.1 Non Alcoholic Fatty Liver Disease Treatment Product Scope
1.1.2 Non Alcoholic Fatty Liver Disease Treatment Market Status and Outlook
1.2 Global Non Alcoholic Fatty Liver Disease Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Region (2018-2029)
1.4 Global Non Alcoholic Fatty Liver Disease Treatment Historic Market Size by Region (2018-2023)
1.5 Global Non Alcoholic Fatty Liver Disease Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Non Alcoholic Fatty Liver Disease Treatment Market Size (2018-2029)
1.6.1 North America Non Alcoholic Fatty Liver Disease Treatment Market Size (2018-2029)
1.6.2 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size (2018-2029)
1.6.4 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size (2018-2029)
2 Non Alcoholic Fatty Liver Disease Treatment Market by Type
2.1 Introduction
2.1.1 Antioxidants
2.1.2 Thiazolidinedione
2.1.3 Biguanides
2.1.4 Lipid lowering Agents
2.1.5 FXR Receptor Agonist
2.1.6 Others
2.2 Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Non Alcoholic Fatty Liver Disease Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Non Alcoholic Fatty Liver Disease Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Non Alcoholic Fatty Liver Disease Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Non Alcoholic Fatty Liver Disease Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Non Alcoholic Fatty Liver Disease Treatment Revenue Breakdown by Type (2018-2029)
3 Non Alcoholic Fatty Liver Disease Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacy
3.1.2 Retail Pharmacy
3.1.3 Drug Stores
3.1.4 Online Pharmacy
3.1.5 Others
3.2 Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Non Alcoholic Fatty Liver Disease Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Non Alcoholic Fatty Liver Disease Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Non Alcoholic Fatty Liver Disease Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Non Alcoholic Fatty Liver Disease Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Non Alcoholic Fatty Liver Disease Treatment Revenue Breakdown by Application (2018-2029)
4 Non Alcoholic Fatty Liver Disease Treatment Competition Analysis by Players
4.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Non Alcoholic Fatty Liver Disease Treatment as of 2022)
4.3 Date of Key Players Enter into Non Alcoholic Fatty Liver Disease Treatment Market
4.4 Global Top Players Non Alcoholic Fatty Liver Disease Treatment Headquarters and Area Served
4.5 Key Players Non Alcoholic Fatty Liver Disease Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Non Alcoholic Fatty Liver Disease Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Non Alcoholic Fatty Liver Disease Treatment Products, Services and Solutions
5.1.4 Pfizer Non Alcoholic Fatty Liver Disease Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Roche
5.2.1 Roche Profile
5.2.2 Roche Main Business
5.2.3 Roche Non Alcoholic Fatty Liver Disease Treatment Products, Services and Solutions
5.2.4 Roche Non Alcoholic Fatty Liver Disease Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Roche Recent Developments
5.3 Daewoong
5.3.1 Daewoong Profile
5.3.2 Daewoong Main Business
5.3.3 Daewoong Non Alcoholic Fatty Liver Disease Treatment Products, Services and Solutions
5.3.4 Daewoong Non Alcoholic Fatty Liver Disease Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Cardax Recent Developments
5.4 Cardax
5.4.1 Cardax Profile
5.4.2 Cardax Main Business
5.4.3 Cardax Non Alcoholic Fatty Liver Disease Treatment Products, Services and Solutions
5.4.4 Cardax Non Alcoholic Fatty Liver Disease Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Cardax Recent Developments
5.5 Merck
5.5.1 Merck Profile
5.5.2 Merck Main Business
5.5.3 Merck Non Alcoholic Fatty Liver Disease Treatment Products, Services and Solutions
5.5.4 Merck Non Alcoholic Fatty Liver Disease Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Merck Recent Developments
5.6 Novartis
5.6.1 Novartis Profile
5.6.2 Novartis Main Business
5.6.3 Novartis Non Alcoholic Fatty Liver Disease Treatment Products, Services and Solutions
5.6.4 Novartis Non Alcoholic Fatty Liver Disease Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Novartis Recent Developments
5.7 Gilead Sciences
5.7.1 Gilead Sciences Profile
5.7.2 Gilead Sciences Main Business
5.7.3 Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Products, Services and Solutions
5.7.4 Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Gilead Sciences Recent Developments
5.8 AstraZeneca
5.8.1 AstraZeneca Profile
5.8.2 AstraZeneca Main Business
5.8.3 AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Products, Services and Solutions
5.8.4 AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 AstraZeneca Recent Developments
5.9 Limerick BioPharma
5.9.1 Limerick BioPharma Profile
5.9.2 Limerick BioPharma Main Business
5.9.3 Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Products, Services and Solutions
5.9.4 Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Limerick BioPharma Recent Developments
5.10 GW Pharmaceuticals
5.10.1 GW Pharmaceuticals Profile
5.10.2 GW Pharmaceuticals Main Business
5.10.3 GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Products, Services and Solutions
5.10.4 GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 GW Pharmaceuticals Recent Developments
5.11 Allergan
5.11.1 Allergan Profile
5.11.2 Allergan Main Business
5.11.3 Allergan Non Alcoholic Fatty Liver Disease Treatment Products, Services and Solutions
5.11.4 Allergan Non Alcoholic Fatty Liver Disease Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 Allergan Recent Developments
5.12 Takeda Pharmaceutical
5.12.1 Takeda Pharmaceutical Profile
5.12.2 Takeda Pharmaceutical Main Business
5.12.3 Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Products, Services and Solutions
5.12.4 Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Revenue (US$ Million) & (2018-2023)
5.12.5 Takeda Pharmaceutical Recent Developments
6 North America
6.1 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Non Alcoholic Fatty Liver Disease Treatment Market Dynamics
11.1 Non Alcoholic Fatty Liver Disease Treatment Industry Trends
11.2 Non Alcoholic Fatty Liver Disease Treatment Market Drivers
11.3 Non Alcoholic Fatty Liver Disease Treatment Market Challenges
11.4 Non Alcoholic Fatty Liver Disease Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
